Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HMGCR | P04035 | 1/20 | 0.36 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.36 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.36 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.34 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.34 |
| ▸ | FFAR3 | O14843 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.31 |
| ▸ | CPT2 | P23786 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14207383 | 0.81 | HMGCR (0.34) | HMGCRCHRM1TBXA2RADRA1ACYP2D6 | |
| SCHEMBL9437569 | 0.81 | HMGCR (0.34) | HMGCRCHRM1TBXA2RADRA1ACYP2D6 | |
| SCHEMBL8568836 | 0.79 | TDP1 (0.38) | TSHRFFAR1CPT2TDP1ALDH1A1 | |
| SCHEMBL6558464 | 0.78 | — | — | |
| SCHEMBL1670466 | 0.73 | HMGCR (0.39) | HMGCRCHRM1TBXA2RADRA1ACYP2D6 | |
| SCHEMBL17849328 | 0.70 | HMGCR (0.40) | HMGCRCHRM1TBXA2RADRA1ACYP2D6 | |
| SCHEMBL25400507 | 0.70 | HMGCR (0.36) | HMGCRCHRM1TBXA2RADRA1ACYP2D6 | |
| SCHEMBL12919196 | 0.69 | — | — | |
| SCHEMBL18751328 | 0.68 | HMGCR (0.44) | HMGCRCHRM1TBXA2RADRA1ACYP2D6 | |
| SCHEMBL4076704 | 0.68 | HMGCR (0.44) | HMGCRCHRM1TBXA2RADRA1ACYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100137566-A1 | Compounds and Methods Used to Treat Infectious Diseases | CYTOKINE PHARMASCIENCES, INC (US) | 2010-06-03 | — | — | US | disclosed |
| US-20060014760-A1 | Compounds and methods of use to treat infectious diseases | BUKRINSKY MICHAEL I | 2006-01-19 | — | — | US | disclosed |
| US-6906076-B2 | Compounds and methods of use to treat infectious diseases | CYTOKINE PHARMASCIENCES, INC. (US) | 2005-06-14 | — | — | US | disclosed |
| US-20040053815-A1 | Compounds and methods of use to treat infectious diseases | FERRING BV (NL) | 2004-03-18 | — | — | US | disclosed |
| EP-0865434-B1 | COMPOUNDS AND THEIR USE TO TREAT INFECTIOUS DISEASES | PICOWER INST MED RES (US) | 2003-12-17 | — | — | EP | disclosed |
| US-6649797-B2 | Contacting protein with a compound that is capable of stable reversible binding with basic amino acid residues of nuclear localization signal of protein for inactivating a nuclear localization signal of a protein | THE PICOWER INSTITUTE FOR MEDICAL RESEARCH | 2003-11-18 | — | — | US | disclosed |
| US-20020077271-A1 | Compounds and methods of use to treat infectious diseases | FERRING BV (NL) | 2002-06-20 | — | — | US | disclosed |
| US-6297253-B1 | INACTIVATING A NUCLEAR LOCALIZATION SIGNAL OF A PROTEIN COMPRISING CONTACTING THE PROTEIN WITH AN ARYL CARBONYL COMPOUND THAT FORMS STABLE REVERSIBLE COVALENT INTERACTIONS WITH NEIGHBORING BASIC AMINO ACID RESIDUES | THE PICOWER INSTITUTE FOR MEDICAL RESEARCH | 2001-10-02 | — | — | US | disclosed |
| US-5840893-A | TREATING MALARIA, HUMAN IMMUNODEFICIENCY VIRUS INFECTIONS | THE PICOWER INSTITUTE FOR MEDICAL RESEARCH (US) | 1998-11-24 | — | — | US | disclosed |
| EP-0865434-A1 | COMPOUNDS AND METHODS OF USE TO TREAT INFECTIOUS DISEASES | THE PICOWER INSTITUTE FOR MEDICAL RESEARCH (US) | 1998-09-23 | — | — | EP | disclosed |
| EP-0865434-A4 | — | — | 1998-09-23 | — | — | EP | disclosed |
| WO-1998016515-A1 | COMPOUNDS AND METHODS TO TREAT INFECTIOUS DISEASES | THE PICOWER INSTITUTE FOR MEDICAL RESEARCH (US) | 1998-04-23 | — | — | WO | disclosed |
| US-5733932-A | VIRICIDES MARKING AND BLOCKING SPECIFIC VIRAL PROTEINS | THE PICOWER INSTITUTE FOR MEDICAL RESEARCH (US) | 1998-03-31 | — | — | US | disclosed |
| US-5703086-A | TREATMENT OF HIV INFECTIONS | THE PICOWER INSTITUTE FOR MEDICAL RESEARCH (US) | 1997-12-30 | — | — | US | disclosed |
| US-5620983-A | BLOCKING MOVEMENT OF VIRAL GENOME PARTICLES THROUGH NUCLEAR MEMBRANE IN TERMINALLY DIFFERENTIATED CELLS TO PREVENT VIRAL INFECTIONS | THE PICOWER INSTITUTE FOR MEDICAL RESEARCH (US) | 1997-04-15 | — | — | US | disclosed |
| US-5574040-A | DIALKANOYLPHENYLPYRIMIDINE DERIVATIVES | PICOWER INSTITUTE FOR MEDICAL RESEARCH (US) | 1996-11-12 | — | — | US | disclosed |
| WO-1996020932-A1 | COMPOUNDS AND METHODS OF USE TO TREAT INFECTIOUS DISEASES | THE PICOWER INSTITUTE FOR MEDICAL RESEARCH (US) | 1996-07-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060014760-A1 | Compounds and methods of use to treat infectious diseases | KPNA1, PHAX, NFATC1 | HMGCR 2024/4885CHRM1 4266/4885TBXA2R 4075/4885 |
| US-20100137566-A1 | Compounds and Methods Used to Treat Infectious Diseases | KPNA1, NFATC1, MAVS | HMGCR 1903/4885CHRM1 4347/4885TBXA2R 3965/4885 |
| US-20020077271-A1 | Compounds and methods of use to treat infectious diseases | KPNA1, PHAX, NFATC1 | HMGCR 2024/4885CHRM1 4266/4885TBXA2R 4075/4885 |
| US-20040053815-A1 | Compounds and methods of use to treat infectious diseases | KPNA1, PHAX, NFATC1 | HMGCR 2024/4885CHRM1 4266/4885TBXA2R 4075/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.